VIR Vir Biotechnology, Inc. Stock Quote

VIR [NASD]

Index	-	P/E	-	EPS (ttm)	-6.40	Insider Own	0.30%	Shs Outstand	125.81M	Perf Week	-18.22%
Market Cap	7.26B	Forward P/E	-	EPS next Y	-2.17	Insider Trans	-36.42%	Shs Float	109.35M	Perf Month	-24.61%
Income	-256.80M	PEG	-	EPS next Q	-0.70	Inst Own	82.80%	Short Float	7.72%	Perf Quarter	130.26%
Sales	75.60M	P/S	96.09	EPS this Y	-443.30%	Inst Trans	4.50%	Short Ratio	5.30	Perf Half Y	43.45%
Book/sh	6.46	P/B	9.70	EPS next Y	9.20%	ROA	-39.40%	Target Price	74.40	Perf Year	4.04%
Cash/sh	7.13	P/C	8.79	EPS next 5Y	8.50%	ROE	-47.10%	52W Range	23.26 - 141.01	Perf YTD	133.87%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-41.90%	52W High	-55.58%	Beta	-
Dividend %	-	Quick Ratio	11.00	Sales past 5Y	-	Gross Margin	-	52W Low	169.26%	ATR	11.08
Employees	297	Current Ratio	11.00	Sales Q/Q	35.70%	Oper. Margin	-	RSI (14)	50.08	Volatility	13.86% 15.84%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-52.30%	Profit Margin	-	Rel Volume	0.60	Prev Close	64.11
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Feb 25 AMC	Payout	-	Avg Volume	1.59M	Price	62.63
Recom	2.10	SMA20	-8.61%	SMA50	28.18%	SMA200	53.77%	Volume	951,088	Change	-2.31%

Jan-27-21

Downgrade

JP Morgan

Neutral → Underweight

$30

Jan-20-21

Reiterated

H.C. Wainwright

Buy

$100 → $125

Oct-05-20

Initiated

BofA Securities

Buy

$55

Sep-14-20

Upgrade

Goldman

Neutral → Buy

$48 → $54

Sep-11-20

Upgrade

JP Morgan

Underweight → Neutral

$29

Aug-20-20

Initiated

Needham

Buy

$62

Mar-19-20

Downgrade

JP Morgan

Neutral → Underweight

$26

Mar-13-20

Downgrade

Goldman

Buy → Neutral

Feb-27-20

Downgrade

Robert W. Baird

Neutral → Underperform

$17

Feb-04-20

Downgrade

JP Morgan

Overweight → Neutral

$25 → $26

Nov-14-19

Initiated

Robert W. Baird

Neutral

Nov-05-19

Initiated

JP Morgan

Overweight

$25

Nov-05-19

Initiated

Goldman

Buy

$37

Nov-05-19

Initiated

Cowen

Outperform

Nov-05-19

Initiated

Barclays

Overweight

$25

Feb-25-21 04:01PM	Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire
Feb-17-21 02:20PM	Vir Biotechnology and GlaxoSmithKline Expand Their Partnership Motley Fool +18.77%
01:00PM	Why Vir Biotechnology Stock Is Higher Today Motley Fool
09:29AM	Vir and GSK Will Collaborate on Flu Therapy Barrons.com
08:10AM	Vir, GSK ink new R&D deal MarketWatch
07:10AM	GSK, Vir Biotech to expand COVID-19 research partnership for other diseases Reuters
07:04AM	GSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Respiratory Viruses GlobeNewswire
Feb-11-21 04:01PM	Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021 GlobeNewswire
Feb-01-21 11:30AM	Reddit-fueled saga a very poor way to stick it to the man, says expert Yahoo Finance Video
10:34AM	Return On Capital Employed Overview: Vir Biotechnology Benzinga
08:00AM	Vir Biotechnology Announces New Data Highlighting the Importance of Targeting Conserved Regions of the SARS-CoV-2 Spike Protein in the Development of Therapeutics GlobeNewswire
07:00AM	Older Investors Might Look to Hop on the GameStop Bandwagon. Why That Could Backfire. Barrons.com
Jan-29-21 12:57PM	An overpriced market is nobody's friend, says finance professor of GameStop Saga Yahoo Finance Video +9.89%
12:22PM	Recapping the weeks Reddit-fueled Wall Street saga Yahoo Finance Video
Jan-28-21 10:28AM	Lilly (LLY) Partners Vir/Glaxo for COVID-19 Combo Regimen Zacks -29.30%
Jan-27-21 01:45PM	Why Vir Biotechnology Stock Is Skyrocketing Today Motley Fool +7.35%
12:40PM	Wall Street Scans Short-Squeeze Targets Amid Reddit Revolution Bloomberg
10:08AM	Vir Will Test Its Covid-19 Antibody With Eli Lillys, Sending Shares Up Again Barrons.com
07:35AM	The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement Benzinga
06:45AM	Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19 PR Newswire
06:45AM	Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19 GlobeNewswire
05:39AM	Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Could Be 31% Below Their Intrinsic Value Estimate Simply Wall St.
Jan-26-21 05:01PM	Why Vir Biotechnology Stock Skyrocketed Today Motley Fool +74.32%
08:00AM	Initial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Demonstrates Significant and Rapid Reduction in Hepatitis B Surface Antigen GlobeNewswire
Jan-20-21 01:43PM	Gilead Stock 2021: Why The Biotech Stock Isn't Depending On Covid Drugs Investor's Business Daily +11.32%
Jan-13-21 02:11PM	Biotech Stock Roundup: Updates From REGN, GILD & VIR, CVAC Teams Up With BAYRY Zacks +10.92%
10:00AM	Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy Zacks
Jan-12-21 04:31PM	Beigene Surges Closer To Breakout On $2.2 Billion Deal With Novartis Investor's Business Daily +13.41%
03:26PM	Why Vir Biotechnology Stock Vaulted Higher Today Motley Fool
08:00AM	Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus Business Wire
03:00AM	Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19 GlobeNewswire
Jan-06-21 08:00AM	Vir Biotechnology Announces Initiation of Phase 1 Clinical Trial to Evaluate a Novel Vaccine Platform GlobeNewswire
Jan-05-21 08:00AM	Vir Biotechnology to Present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-22-20 11:00AM	Are Options Traders Betting on a Big Move in in Vir Biotechnology (VIR) Stock? Zacks
Dec-18-20 09:12AM	Vir, GSK's experimental COVID-19 treatment moves into a Phase 3 clinical trial MarketWatch -5.68%
07:45AM	The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data Benzinga
Dec-17-20 04:01PM	Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19 GlobeNewswire
Dec-10-20 08:00AM	Vir Biotechnology Appoints Jeffrey Hatfield to its Board of Directors GlobeNewswire +9.24%
Dec-08-20 01:09PM	Vaccines Alone Arent Enough to Beat Covid-19 Bloomberg
Dec-04-20 10:11AM	Vaccines and Approved Antibodies Dim Vir Biotechnologys Covid Opportunity, Analyst Says Barrons.com
Dec-02-20 03:51PM	Is Vir Biotechnology (VIR) A Good Stock To Buy Now? Insider Monkey
Nov-24-20 09:47AM	Vir Biotech CEO Says His Covid-19 Medicine Offers Promise for Next Outbreak Bloomberg
Nov-16-20 02:55AM	Analysts Have Just Cut Their Vir Biotechnology, Inc. (NASDAQ:VIR) Revenue Estimates By 20% Simply Wall St.
Nov-13-20 09:08AM	Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts Simply Wall St.
Nov-10-20 04:01PM	Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2020 Financial Results GlobeNewswire
Nov-06-20 08:00AM	Vir Biotechnology Publishes New Research Characterizing Variation in the SARS-CoV-2 Spike Protein and Virulence of a Prevalent Immune Evasion Variant, N439K GlobeNewswire
Oct-27-20 04:01PM	Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2020 Financial Results on November 10, 2020 GlobeNewswire
Oct-21-20 08:00AM	Vir Biotechnology Presents New Data on VIR-2482, the Companys Investigational Monoclonal Antibody for the Prevention of Influenza A, at IDWeek 2020 GlobeNewswire
Oct-13-20 04:01PM	Vir and Alnylam to Webcast Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus Mini-Conference GlobeNewswire
11:26AM	How Much Of Vir Biotechnology, Inc. (NASDAQ:VIR) Do Insiders Own? Simply Wall St.
Oct-12-20 09:31AM	3 COVID-19 Antibody Stocks That Are Leading the Race TipRanks +6.09%
Oct-09-20 08:00AM	Nature Publishes New Research from Vir Biotechnology Demonstrating the Capacity of Enhanced Monoclonal Antibodies to Induce Protective Adaptive Immunity to Viral Infection GlobeNewswire
Oct-07-20 01:44PM	Lilly Serves Up an Anti-Covid Cocktail, Like Regenerons. The Stock Is Rising. Barrons.com
01:01PM	Vir Biotech, Glaxo Begin Phase III Study on Coronavirus Therapy Zacks
08:47AM	Vir Biotechnology (VIR) Looks Good: Stock Adds 6% in Session Zacks
07:24AM	Vir Biotechnology Kicks Off Covid-19 Treatment Trial; Shares Rise 6.1% SmarterAnalyst
Oct-06-20 04:25PM	Vir Biotechnology, GlaxoSmithKline Expanding Phase 3 Trials For Covid-19 Treatment Investor's Business Daily +6.11%
11:28AM	Vir Biotech, GlaxoSmithKline Advance COVID-19 Antibody Treatment Into Global, Late-Stage Trial Benzinga
10:46AM	Vir Biotechnology Stock Rises as It Preps for Covid Antibody Phase 3 Trial Barrons.com
10:03AM	Vir's stock rises as COVID-19 drug moves to late-study clinical trial MarketWatch
09:49AM	Return On Capital Employed Overview: Vir Biotechnology Benzinga
08:18AM	Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19 GlobeNewswire
Sep-29-20 06:08PM	Regeneron Says Antibodies Helped Covid Patients Recover Faster. Here Are the Next Steps. Barrons.com
Sep-26-20 06:16AM	Better Coronavirus Stock: BioNTech or Vir Biotechnology? Motley Fool
Sep-24-20 08:00AM	Vir Biotechnology Publishes New Research Characterizing Antibody Response to SARS-CoV-2 in the Journal Cell GlobeNewswire
Sep-23-20 12:41PM	The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX Zacks
Sep-22-20 10:01AM	4 Biotechs That Have More Than Doubled Thanks to Coronavirus Zacks
09:43AM	Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 50% TipRanks
Sep-15-20 06:30AM	Should You Buy Vir Biotechnology Stock on the Dip? Motley Fool
Sep-09-20 04:10PM	Vir Biotechnology to Present at Cantor Global Virtual Healthcare Conference GlobeNewswire +5.20%
Sep-08-20 04:01PM	Vir Biotechnology to Present at H.C. Wainwright 22nd Annual Global Investment Conference GlobeNewswire
Sep-02-20 07:25AM	The Daily Biotech Pulse: Amarin's Vascepa Appeal Hearing, Avid Bioservices' Strong Q1, A Life Sciences Blank Check IPO Benzinga
Sep-01-20 04:01PM	Vir Biotechnology Appoints Janet Napolitano to its Board of Directors GlobeNewswire -16.28%
09:39AM	Glaxo/Vir Biotech Begin Clinical Study on Coronavirus Therapy Zacks
09:09AM	Sanofi and Regeneron Give Up On Arthritis Drug to Treat Covid-19. Why Thats OK. Barrons.com
Aug-31-20 03:39PM	Coronavirus Latest: Monday, August 31 Yahoo Finance Video
03:17PM	Vir Biotechnology and GSK Launch Phase 2/3 Study of COVID-19 Antibody Motley Fool
12:45PM	Coronavirus update: FDA sparks new debate over 'following Russia, China' in vaccine push Yahoo Finance
08:50AM	Vir and GSK start Phase 2/3 trial for experimental COVID-19 treatment MarketWatch
08:00AM	Vir Biotechnology and GSK Start Phase 2/3 Study of COVID-19 Antibody Treatment GlobeNewswire
Aug-20-20 09:51AM	Benzinga's Top Upgrades, Downgrades For August 20, 2020 Benzinga
08:00AM	Vir Biotechnology Presents Data on VIR-2218 from Clinical Studies for the Treatment of Hepatitis B at the EASL Digital International Liver Congress GlobeNewswire
Aug-11-20 04:01PM	Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2020 Financial Results GlobeNewswire
06:40AM	SoftBank Moves Into Asset Management After Return to Profits Bloomberg
Jul-28-20 04:01PM	Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2020 Financial Results on August 11, 2020 GlobeNewswire
Jul-10-20 04:02PM	Vir Biotechnology Appoints Elliott Sigal, M.D., Ph.D. to Board of Directors GlobeNewswire
04:01PM	Vir Biotechnology Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-07-20 10:25PM	Vir Biotechnology Announces Pricing of Public Offering of Common Stock GlobeNewswire +8.12%
05:58PM	U.S. Cases Rise 1.8%; Texas Infections Hit Record: Virus Update Bloomberg
Jul-06-20 07:00AM	Vir Biotechnology Announces Proposed Public Offering of Common Stock GlobeNewswire
Jun-08-20 02:06PM	Here's Why Vir Biotechnology Jumped 12% in May Motley Fool +8.22%
Jun-05-20 01:22PM	Antibody Drugs Could Help Curb the Pandemic. What Investors Need to Know. Barrons.com
Jun-04-20 03:57PM	Vir Biotechnology, Inc. (VIR): Hedge Funds Arent Enthusiastic Insider Monkey
Jun-02-20 08:00AM	Dont Only Bet on Fast Vaccines, Root for Covid Treatments Bloomberg
Jun-01-20 12:23PM	Vir Biotechnology Is Bucking The Biotech COVID-19 Trends, And Stands To Win Motley Fool
11:00AM	3 Biotech Quick Picks to Invest $5,000 This Week Motley Fool
May-29-20 08:00AM	Vir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment GlobeNewswire +8.30%
May-27-20 08:00AM	Vir Biotechnology Initiates Phase 1 Clinical Trial of VIR-3434 for Chronic Hepatitis B Virus Infection GlobeNewswire
May-23-20 08:13AM	Better Coronavirus Stock: Gilead Sciences or Vir Biotechnology? Motley Fool
May-19-20 09:31AM	Company News for May 19, 2020 Zacks -15.26%

Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Virgin Herbert	EVP, Research & CSO	Feb 23	Option Exercise	1.53	18,900	28,917	82,100	Feb 25 04:25 PM
Virgin Herbert	EVP, Research & CSO	Feb 23	Sale	63.74	7,900	503,577	74,200	Feb 25 04:25 PM
Pang Phillip	Chief Medical Officer	Feb 16	Option Exercise	0.86	10,000	8,550	77,277	Feb 18 05:01 PM
Pang Phillip	Chief Medical Officer	Feb 12	Option Exercise	0.86	10,000	8,550	67,277	Feb 17 05:25 PM
Virgin Herbert	EVP, Research & CSO	Feb 09	Option Exercise	1.53	7,900	12,087	41,100	Feb 10 04:33 PM
Virgin Herbert	EVP, Research & CSO	Feb 09	Sale	71.16	7,900	562,161	33,200	Feb 10 04:33 PM
Parrish Jay	Chief Business Officer	Feb 01	Option Exercise	1.55	6,944	10,729	229,166	Feb 02 06:00 PM
Parrish Jay	Chief Business Officer	Feb 01	Sale	69.91	6,944	485,424	222,222	Feb 02 06:00 PM
Virgin Herbert	EVP, Research & CSO	Jan 26	Option Exercise	1.53	31,300	47,889	64,500	Jan 27 06:39 PM
Virgin Herbert	EVP, Research & CSO	Jan 26	Sale	48.17	31,300	1,507,806	33,200	Jan 27 06:39 PM
Virgin Herbert	EVP, Research & CSO	Jan 15	Option Exercise	1.53	10,530	16,111	43,730	Jan 19 05:00 PM
Virgin Herbert	EVP, Research & CSO	Jan 15	Sale	38.00	10,530	400,140	33,200	Jan 19 05:00 PM
Virgin Herbert	EVP, Research & CSO	Jan 12	Option Exercise	1.53	3,805	5,822	37,005	Jan 13 06:38 PM
Virgin Herbert	EVP, Research & CSO	Jan 12	Sale	29.36	3,805	111,696	33,200	Jan 13 06:38 PM
Parrish Jay	Chief Business Officer	Jan 04	Option Exercise	1.49	6,945	10,313	229,167	Jan 05 04:40 PM
Parrish Jay	Chief Business Officer	Jan 04	Sale	26.32	6,945	182,795	222,222	Jan 05 04:40 PM
Virgin Herbert	EVP, Research & CSO	Dec 24	Option Exercise	1.53	9,500	14,535	33,200	Dec 28 06:39 PM
Virgin Herbert	EVP, Research & CSO	Dec 22	Option Exercise	1.53	3,805	5,822	27,505	Dec 23 06:06 PM
Virgin Herbert	EVP, Research & CSO	Dec 22	Sale	31.19	3,805	118,683	23,700	Dec 23 06:06 PM
Virgin Herbert	EVP, Research & CSO	Dec 08	Option Exercise	1.53	3,805	5,822	27,505	Dec 10 05:00 PM
Virgin Herbert	EVP, Research & CSO	Dec 08	Sale	31.27	3,805	118,966	23,700	Dec 10 05:00 PM
Parrish Jay	Chief Business Officer	Dec 01	Option Exercise	1.52	6,945	10,522	229,167	Dec 02 05:48 PM
Parrish Jay	Chief Business Officer	Dec 01	Sale	31.53	6,945	218,968	222,222	Dec 02 05:48 PM
Virgin Herbert	EVP, Research & CSO	Nov 27	Option Exercise	1.53	2,930	4,483	26,630	Dec 01 07:02 PM
Pang Phillip	Chief Medical Officer	Nov 27	Option Exercise	0.86	7,500	6,413	57,277	Dec 01 07:03 PM
Virgin Herbert	EVP, Research & CSO	Nov 27	Sale	30.00	2,930	87,900	23,700	Dec 01 07:02 PM
Virgin Herbert	EVP, Research & CSO	Nov 24	Option Exercise	1.53	2,340	3,580	26,040	Nov 25 05:00 PM
Virgin Herbert	EVP, Research & CSO	Nov 24	Sale	27.29	2,340	63,848	23,700	Nov 25 05:00 PM
Pang Phillip	Chief Medical Officer	Nov 12	Option Exercise	0.86	20,000	17,100	49,777	Nov 16 05:00 PM
Virgin Herbert	EVP, Research & CSO	Nov 10	Option Exercise	1.53	2,340	3,580	26,040	Nov 12 05:00 PM
Virgin Herbert	EVP, Research & CSO	Nov 10	Sale	26.26	2,340	61,448	23,700	Nov 12 05:00 PM
Pang Phillip	Chief Medical Officer	Nov 04	Option Exercise	1.53	5,000	7,650	34,777	Nov 05 05:00 PM
Parrish Jay	Chief Business Officer	Nov 02	Option Exercise	1.52	6,944	10,520	229,166	Nov 03 05:00 PM
Parrish Jay	Chief Business Officer	Nov 02	Sale	31.27	6,944	217,153	222,222	Nov 03 05:00 PM
Virgin Herbert	EVP, Research & CSO	Oct 27	Option Exercise	1.53	3,805	5,822	27,505	Oct 28 07:43 PM
Virgin Herbert	EVP, Research & CSO	Oct 27	Sale	35.04	3,805	133,335	23,700	Oct 28 07:43 PM
Pang Phillip	Chief Medical Officer	Oct 21	Option Exercise	2.21	12,500	27,667	42,277	Oct 22 06:15 PM
Pang Phillip	Chief Medical Officer	Oct 21	Sale	35.49	12,500	443,608	29,777	Oct 22 06:15 PM
Pang Phillip	Chief Medical Officer	Oct 21	Sale	31.44	5,000	157,209	29,777	Nov 05 05:00 PM
Virgin Herbert	EVP, Research & CSO	Oct 13	Option Exercise	1.53	5,560	8,507	29,260	Oct 14 06:33 PM
Virgin Herbert	EVP, Research & CSO	Oct 13	Sale	43.03	5,560	239,236	23,700	Oct 14 06:33 PM
Pang Phillip	Chief Medical Officer	Oct 07	Option Exercise	1.54	12,500	19,229	42,277	Oct 08 05:00 PM
Pang Phillip	Chief Medical Officer	Oct 07	Sale	41.74	12,500	521,795	29,777	Oct 08 05:00 PM
Parrish Jay	Chief Business Officer	Oct 01	Option Exercise	1.52	6,945	10,522	229,167	Oct 02 05:19 PM
Parrish Jay	Chief Business Officer	Oct 01	Sale	34.75	6,945	241,342	222,222	Oct 02 05:19 PM
Virgin Herbert	EVP, Research & CSO	Sep 29	Option Exercise	1.53	3,510	5,370	27,210	Oct 01 05:00 PM
Virgin Herbert	EVP, Research & CSO	Sep 29	Sale	38.00	3,510	133,380	23,700	Oct 01 05:00 PM
Virgin Herbert	EVP, Research & CSO	Sep 24	Option Exercise	1.53	3,700	5,661	23,700	Sep 28 05:00 PM
Virgin Herbert	EVP, Research & CSO	Sep 22	Option Exercise	1.53	3,805	5,822	23,805	Sep 23 05:00 PM
Virgin Herbert	EVP, Research & CSO	Sep 22	Sale	31.71	3,805	120,638	20,000	Sep 23 05:00 PM
Pang Phillip	Chief Medical Officer	Sep 16	Option Exercise	2.24	12,500	28,001	42,277	Sep 18 05:00 PM
Pang Phillip	Chief Medical Officer	Sep 16	Sale	31.90	12,500	398,694	29,777	Sep 18 05:00 PM
Virgin Herbert	EVP, Research & CSO	Sep 08	Option Exercise	1.53	3,805	5,822	23,805	Sep 10 04:30 PM
Virgin Herbert	EVP, Research & CSO	Sep 08	Sale	29.99	3,805	114,098	20,000	Sep 10 04:30 PM
Pang Phillip	Chief Medical Officer	Sep 02	Option Exercise	1.58	12,500	19,688	42,277	Sep 03 04:23 PM
Pang Phillip	Chief Medical Officer	Sep 02	Sale	32.89	12,500	411,159	29,777	Sep 03 04:23 PM
Parrish Jay	Chief Business Officer	Sep 01	Option Exercise	1.58	6,943	10,935	229,165	Sep 03 04:22 PM
Parrish Jay	Chief Business Officer	Sep 01	Sale	39.15	6,943	271,796	222,222	Sep 03 04:22 PM
Virgin Herbert	EVP, Research & CSO	Aug 25	Option Exercise	1.53	25,560	39,107	25,560	Sep 10 04:29 PM
Virgin Herbert	EVP, Research & CSO	Aug 25	Sale	42.92	5,560	238,632	20,000	Sep 10 04:29 PM
Pang Phillip	Chief Medical Officer	Aug 19	Option Exercise	1.51	26,500	39,992	42,277	Aug 21 04:39 PM
Pang Phillip	Chief Medical Officer	Aug 19	Sale	50.95	12,500	636,855	29,777	Aug 21 04:39 PM
Virgin Herbert	EVP, Research & CSO	Aug 11	Option Exercise	1.53	7,900	12,087	7,900	Aug 12 04:30 PM
Virgin Herbert	EVP, Research & CSO	Aug 11	Sale	51.08	7,900	403,563	0	Aug 12 04:30 PM
Pang Phillip	Chief Medical Officer	Aug 05	Option Exercise	1.58	12,500	19,688	28,277	Aug 07 05:40 PM
Pang Phillip	Chief Medical Officer	Aug 05	Option Exercise	1.58	12,500	19,688	28,277	Aug 07 05:07 PM
Pang Phillip	Chief Medical Officer	Aug 05	Sale	50.90	12,500	636,222	15,777	Aug 07 05:07 PM
Pang Phillip	Chief Medical Officer	Aug 05	Sale	50.90	12,500	636,222	15,777	Aug 07 05:40 PM
Parrish Jay	Chief Business Officer	Aug 03	Option Exercise	1.50	11,110	16,665	233,332	Aug 04 05:14 PM
Parrish Jay	Chief Business Officer	Aug 03	Sale	47.65	11,110	529,404	222,222	Aug 04 05:14 PM
Virgin Herbert	EVP, Research & CSO	Jul 28	Option Exercise	1.53	7,900	12,087	7,900	Jul 30 07:28 PM
Virgin Herbert	EVP, Research & CSO	Jul 28	Option Exercise	1.53	7,900	12,087	7,900	Jul 30 07:03 PM
Virgin Herbert	EVP, Research & CSO	Jul 28	Sale	47.99	7,900	379,090	0	Jul 30 07:03 PM
Virgin Herbert	EVP, Research & CSO	Jul 28	Sale	47.99	7,900	379,090	0	Jul 30 07:28 PM
Pang Phillip	Chief Medical Officer	Jul 15	Option Exercise	2.24	12,500	28,018	28,277	Jul 16 05:00 PM
Pang Phillip	Chief Medical Officer	Jul 15	Sale	49.53	12,500	619,118	15,777	Jul 16 05:00 PM
Virgin Herbert	EVP, Research & CSO	Jul 14	Option Exercise	1.53	7,900	12,087	7,900	Jul 16 05:00 PM
Virgin Herbert	EVP, Research & CSO	Jul 14	Sale	48.85	7,900	385,876	0	Jul 16 05:00 PM
Horn Howard	CFO	Jul 13	Sale	50.06	30,000	1,501,731	177,777	Jul 15 04:50 PM
Horn Howard	CFO	Jul 02	Sale	40.00	10,000	400,000	207,777	Jul 02 06:42 PM
Pang Phillip	Chief Medical Officer	Jul 01	Option Exercise	4.37	12,500	54,687	28,277	Jul 02 06:42 PM
Parrish Jay	Chief Business Officer	Jul 01	Option Exercise	1.54	75,000	115,792	297,222	Jul 02 06:43 PM
Horn Howard	CFO	Jul 01	Sale	37.84	10,000	378,399	217,777	Jul 02 06:42 PM
Pang Phillip	Chief Medical Officer	Jul 01	Sale	37.78	12,500	472,252	15,777	Jul 02 06:42 PM
Parrish Jay	Chief Business Officer	Jul 01	Sale	37.95	75,000	2,846,310	222,222	Jul 02 06:43 PM
Horn Howard	CFO	Jun 25	Sale	50.00	30,000	1,500,000	227,777	Jun 26 05:00 PM
Virgin Herbert	EVP, Research & CSO	Jun 24	Option Exercise	1.53	9,360	14,321	9,360	Jun 24 08:23 PM
Virgin Herbert	EVP, Research & CSO	Jun 24	Sale	48.00	9,360	449,280	0	Jun 24 08:23 PM
Virgin Herbert	EVP, Research & CSO	Jun 23	Option Exercise	1.53	5,560	8,507	5,560	Jun 24 08:23 PM
Virgin Herbert	EVP, Research & CSO	Jun 23	Sale	38.99	5,560	216,778	0	Jun 24 08:23 PM
Virgin Herbert	EVP, Research & CSO	Jun 19	Option Exercise	1.53	3,510	5,370	3,510	Jun 23 05:00 PM
Virgin Herbert	EVP, Research & CSO	Jun 19	Sale	38.00	3,510	133,384	0	Jun 23 05:00 PM
Horn Howard	CFO	Jun 19	Sale	40.00	10,000	400,000	257,777	Jun 23 05:00 PM
Pang Phillip	Chief Medical Officer	Jun 17	Option Exercise	5.18	12,500	64,688	28,277	Jun 18 05:00 PM
Pang Phillip	Chief Medical Officer	Jun 17	Sale	37.27	12,500	465,815	15,777	Jun 18 05:00 PM
Virgin Herbert	EVP, Research & CSO	Jun 09	Option Exercise	1.53	3,805	5,822	3,805	Jun 11 05:00 PM
Virgin Herbert	EVP, Research & CSO	Jun 09	Sale	36.28	3,805	138,030	0	Jun 11 05:00 PM
Pang Phillip	Chief Medical Officer	Jun 03	Option Exercise	5.18	12,500	64,688	28,277	Jun 04 04:53 PM
Pang Phillip	Chief Medical Officer	Jun 03	Sale	35.07	12,500	438,387	15,777	Jun 04 04:53 PM
Parrish Jay	Chief Business Officer	Jun 01	Option Exercise	1.49	75,000	111,375	297,222	Jun 02 09:15 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience